急性髓系白血病靶向治疗进展

Progress in Targeted Therapy of Acute Myeloid Leukemia

急性髓系白血病是一类以克隆性髓系原始细胞增高为主的造血系统恶性疾病,其发病机制尚不完全清楚,严重危害患者的生活质量及生存期。现临床治疗以联合化疗为主,部分患者因身体一般状况差或伴随严重器质性疾病不能耐受传统治疗,导致患者生存率较低,用药耐受性较差。随着分子生物学及免疫学的不断发展,对疾病的发病机制不断取得新的突破,也使得靶向治疗及免疫治疗成为可能。本文就急性髓系白血病的治疗进展做一相关综述。

Acute myeloid leukemia is a kind of hematopoietic malignant disease mainly characterized by the increase of clonal myeloid primitive cells, its pathogenesis is not fully understood, which seriously endangers the quality of life and survival of patients. At present, combined chemotherapy is the main clinical treatment.Some patients cannot tolerate traditional treatment due to poor general physical condition or accompanied by serious organic diseases, resulting in low survival rate and poor drug tolerance. With the continuous development of molecular biology and immunology, new breakthroughs have been made in the pathogenesis of diseases, which also makes targeted therapy and immunotherapy possible. This article reviews the progress in the treatment of acute myeloid leukemia.